drugset / Trial / NCT04074330
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is about a medicine called TAK-981 given with rituximab, used to treat adults with relapsed or refractory CD20-positive non-Hodgkin lymphoma. This study has 2 parts. The main aims of the study are: * To check for side effects from treatment with TAK-981 given with rituximab. * To check how much TAK-981 participants can tolerate. * To check if participants with diffuse large B-cell lymphoma or follicular lymphoma respond well to treatment. Participants will receive TAK-981 and rituximab in 21-day cycles. They will continue treatment for about 12 months unless their condition gets worse (disease progression), they cannot tolerate the treatment, or they leave the study for certain reasons.
Timeline
- Start
- 2019-10-15
- Primary completion
- 2023-04-26
- Completion
- 2023-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | TAK-981 | Small molecule | 10 mg | Intravenous |
| Subject | TAK-981 | Small molecule | 40 mg | Intravenous |
| Subject | TAK-981 | Small molecule | 60 mg | Intravenous |
| Subject | TAK-981 | Small molecule | 90 mg | Intravenous |
| Subject | TAK-981 | Small molecule | 120 mg | Intravenous |